SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Day After Intercept’s Setback, Akero’s EFX Shows Promise in NASH Trial
Of the 40 patients who responded who had end-of-treatment biopsies, 48% showed at least a one-stage improvement in fibrosis without worsening of NAFLD activity score and 28% demonstrated at least a two-stage improvement in fibrosis.
July 1, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: July 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
June 30, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: June 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
June 29, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Clinical Catch-Up: June 22-26
It was a busy week for clinical trial updates. Here’s a look.
June 26, 2020
 · 
7 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
June 25, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: June 24
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
June 23, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Ridgeback Aims Antiviral at COVID-19 in Two Phase II Studies
Ridgeback Therapeutics will launch two mid-stage programs assessing the efficacy of its antiviral candidate EIDD-2801 as a treatment for COVID-19.
June 22, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: June 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
June 22, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Evelo Stock Soars After Asset Tapped for Phase II/III COVID-19 Study in the U.K.
The TACTIC-E trial will investigate the safety and efficacy of experimental therapies designed to prevent and treat life-threatening complications associated with COVID-19 in hospitalized patients who are at early stages of the disease.
June 22, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Clinical Catch-Up: June 15-19
It was a busy week for clinical trial announcements. Here’s a look.
June 19, 2020
 · 
12 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Drug Development
Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)
July 24, 2023
 · 
10 min read
Drug Development
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
July 24, 2023
 · 
2 min read
Drug Development
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint
July 21, 2023
 · 
3 min read
Drug Development
SunHo Announces First Patient Dosed in Phase I/II Clinical Trial of a Potential First-in-class Immunocytokine IBB0979
July 21, 2023
 · 
2 min read
Drug Development
Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies
July 21, 2023
 · 
2 min read
Drug Development
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 20, 2023
 · 
4 min read
Drug Development
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
July 20, 2023
 · 
3 min read
Drug Development
Sentynl Therapeutics Supports Phase 2 of Rady Children’s Institute for Genomic Medicine® BeginNGS™ Program to Identify Treatable Genetic Diseases in Newborns
July 20, 2023
 · 
3 min read
Drug Development
Perfuse Therapeutics Announces Initiation of Enrollment to Ph2a portion of the Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma
July 20, 2023
 · 
3 min read
Drug Development
Promontory Therapeutics Expands Phase 2 Trial of PT-112 in Metastatic Castrate-Resistant Prostate Cancer to France
July 20, 2023
 · 
4 min read
Drug Development
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
July 20, 2023
 · 
7 min read
Drug Development
Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
July 19, 2023
 · 
3 min read
Drug Development
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
July 19, 2023
 · 
12 min read
Drug Development
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
July 19, 2023
 · 
8 min read
Drug Development
Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic
July 19, 2023
 · 
4 min read
Drug Development
ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia
July 19, 2023
 · 
2 min read
Drug Development
Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS
July 19, 2023
 · 
5 min read
Drug Development
MindBio Therapeutics World First Phase 2 Take-Home LSD-Microdosing Clinical Trial in Patients with Major Depressive Disorder Begins Pre-Screening Participants
July 19, 2023
 · 
5 min read
Drug Development
Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update
July 19, 2023
 · 
7 min read
Drug Development
First patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitis
July 19, 2023
 · 
3 min read
Load More